Published in Transplantation on May 01, 1991
Infections in solid-organ transplant recipients. Clin Microbiol Rev (1997) 2.86
NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant (2015) 1.14
Liver transplantation in the UK. World J Gastroenterol (2001) 1.02
Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation (2000) 0.95
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl (2001) 0.93
Mycophenolate mofetil for drug-induced vanishing bile duct syndrome. World J Gastroenterol (2007) 0.85
Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant (1997) 0.79
Cytokeratin immunostaining for detection of biliary epithelium: its use in counting bile ducts in cases of liver allograft rejection. J Clin Pathol (1994) 0.79
[Current aspects of liver allograft pathology]. Pathologe (2011) 0.79
Risk factors for liver rejection: evidence to suggest enhanced allograft tolerance in infancy. Arch Dis Child (1996) 0.79
Pathology of Chronic Rejection: An Overview of Common Findings and Observations About Pathogenic Mechanisms and Possible Prevention. Graft (Georget Tex) (1998) 0.76
Aspects of liver transplant pathology with emphasis on rejection and its mechanisms. J Clin Pathol (1994) 0.75
[Histopathology in liver transplantation]. Pathologe (2008) 0.75
Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet (1979) 12.29
Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet (1979) 6.10
Elective ventilation of potential organ donors. BMJ (1995) 5.50
Diagnostic importance of changes in circulating concentrations of immunoreactive trypsin. Lancet (1977) 3.43
Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. Aliment Pharmacol Ther (2014) 3.39
Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut (1999) 3.10
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology (1996) 2.99
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation (2000) 2.90
The NHS as a theological institution. The ideal remains strong, but the practice too has to measure up. BMJ (2000) 2.81
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Offering choice of treatment to patients with cancers. A review based on a symposium held at the 10th annual conference of The British Psychosocial Oncology Group, December 1993. Eur J Cancer (1995) 2.66
Cholangiography in the jaundiced patient. Gut (1976) 2.44
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol (2001) 2.39
Medical evacuation from Mostar. Lancet (1996) 2.37
Financial ties as part of informed consent to postmarketing research. Attitudes of American doctors and patients. BMJ (1995) 2.36
Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32
A randomized trial of percutaneous transhepatic cholangiography with the Chiba needle versus endoscopic retrograde cholangiography for bile duct visualization in jaundice. Gastroenterology (1976) 2.25
Selective decontamination of the digestive tract reduces gram-negative pulmonary colonization but not systemic endotoxemia in patients undergoing elective liver transplantation. Crit Care Med (1994) 2.21
Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut (2000) 2.16
Serum trypsin concentrations in diabetes mellitus. Br Med J (1978) 2.09
Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ (1996) 2.04
Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. Lancet (2000) 1.99
Cyclosporin A: preliminary observations in dogs with pancreatic duodenal allografts and patients with cadaveric renal transplants. Transplant Proc (1979) 1.94
Computerised protocols for laboratory investigation and their effect on use of medical time and resources. J Clin Pathol (1992) 1.87
Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology (1985) 1.86
Clinical spectrum, investigations and treatment of Budd-Chiari syndrome. QJM (1996) 1.81
Bile duct injury following laparoscopic cholecystectomy: referral pattern and management. Br J Surg (1997) 1.81
Managing Budd-Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting. Gut (1999) 1.80
Acute polymyositis in an adult associated with Mycoplasma pneumoniae infection. Postgrad Med J (1990) 1.80
The slowing of gastric emptying by monosaccharides and disaccharides in test meals. J Physiol (1968) 1.79
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet (1996) 1.78
Neurological complications following liver transplantation. Lancet (1987) 1.76
Clinical guidelines on the management of hepatitis C. Gut (2001) 1.72
Wilson's disease with superimposed autoimmune features: report of two cases and review. J Gastroenterol Hepatol (2000) 1.70
Native and recombinant human hepatocyte growth factors are highly potent promoters of DNA synthesis in both human and rat hepatocytes. J Clin Invest (1991) 1.70
Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation. Lancet (1987) 1.68
Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut (1997) 1.66
Liver resection for colorectal metastases. Ann R Coll Surg Engl (2003) 1.66
Delay in presentation of symptomatic referrals to a breast clinic: patient and system factors. Br J Cancer (2000) 1.66
Treatment of hydatid disease of the liver. Evaluation of a UK experience. Dig Surg (2004) 1.65
Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant (2010) 1.64
Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med (1982) 1.64
Clinical heterogeneity associated with deletions in the long arm of chromosome 15: report of 3 new cases and their possible genetic significance. Am J Med Genet (1987) 1.62
Radiological intervention in Budd-Chiari syndrome: techniques and outcome in 18 patients. Clin Radiol (1996) 1.57
Sulphoxidation and sulphation capacity in patients with primary biliary cirrhosis. J Hepatol (1995) 1.54
Halothane hepatitis: a model of immune mediated drug hepatotoxicity. Clin Sci (Lond) (1987) 1.54
Recovery despite impaired cerebral perfusion in fulminant hepatic failure. Lancet (1994) 1.53
Observations on preservation, bile drainage and rejection in 64 human orthotopic liver allografts. Ann Surg (1977) 1.53
Chronic pancreatitis: a cause of cholestasis. Gut (1977) 1.51
Role of users of health care in achieving a quality service. Qual Health Care (1994) 1.49
Hydatid liver disease as a cause of recurrent pancreatitis. J R Coll Surg Edinb (1999) 1.49
A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion (2000) 1.48
Pancreatic cholera due to production of gastric inhibitory polypeptide. Lancet (1972) 1.44
Enhanced (cytomegalovirus) viral replication after transplantation for fulminant hepatic failure. Liver Transpl Surg (1997) 1.44
Association of spinocerebellar disorders with cystic fibrosis or chronic childhood cholestasis and very low serum vitamin E. Lancet (1981) 1.40
Colonic Crohn's disease and use of oral contraception. Br Med J (Clin Res Ed) (1984) 1.40
Successful pregnancy in a patient with type III glycogen storage disease managed with cornstarch supplements. Br J Obstet Gynaecol (1998) 1.40
Cerebral aspergillosis in liver transplantation. J Clin Pathol (1990) 1.40
Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet (2000) 1.39
Serum lipids and apolipoproteins in liver transplant recipients: a comparative study of cyclosporin A and FK 506. J Lab Clin Med (1994) 1.39
Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant (2009) 1.39
Prolongation of canine pancreas allograft survival with cyclosporin A: preliminary report. Br Med J (1980) 1.38
Ageing Britain--challenges and opportunities for general practice. Br J Gen Pract (2001) 1.38
Liver transplantation for alcoholic cirrhosis: current situation. Hosp Med (1998) 1.38
Oral-contraceptive-associated liver tumours: occurrence of malignancy and difficulties in diagnosis. Lancet (1980) 1.37
Primary hepatic malignancy: the role of liver transplantation. Br J Surg (1990) 1.34
Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit (1995) 1.30
GSTM1 null polymorphism at the glutathione S-transferase M1 locus: phenotype and genotype studies in patients with primary biliary cirrhosis. Gut (1993) 1.30
Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol (2004) 1.28
Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis. J Lab Clin Med (1976) 1.27
Oxidative metabolism of halothane in the production of altered hepatocyte membrane antigens in acute halothane-induced hepatic necrosis. Gut (1981) 1.27
Halothane anaesthesia and liver damage. Br Med J (Clin Res Ed) (1984) 1.24
Long-term use of cyclosporin in liver grafting. Q J Med (1985) 1.24
Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis. Eur J Gastroenterol Hepatol (1997) 1.24
Biopsy findings in cases of rejection of liver allograft. J Clin Pathol (1985) 1.24
Use of a prognostic index in evaluation of liver transplantation for primary biliary cirrhosis. Transplantation (1986) 1.24
Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. Liver Transpl (2001) 1.24
Endoscopic retrograde cholangiopancreatography in the diagnosis of jaundice associated with ulcerative colitis. Gastroenterology (1974) 1.22
An unusual case of duodenal obstruction-gangliocytic paraganglioma. J Hepatobiliary Pancreat Surg (2009) 1.21
The treatment of major liver trauma by primary packing with transfer of the patient for definitive treatment. Br J Surg (1979) 1.20
Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. QJM (2000) 1.18
Fulminant hepatic failure caused by tuberculosis. Gut (1995) 1.18
Oral contraceptives and hepatocellular carcinoma. Br Med J (Clin Res Ed) (1986) 1.18
High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol (1999) 1.17
Sclerosing cholangitis associated with multifocal fibrosis: a case report. Gut (1992) 1.17